A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in participants with high-risk and very high-risk localised/locally advanced prostate cancer with a breast cancer gene mutation (BRCAm).

NCT Number	NCT06952803
Lead Sponsor	AstraZeneca Collaborators: Parexel
Conditions	Prostate Cancer
Enrollment	700 participants
Start Date	2025-08-06
Primary Completion	2033-03-31 (estimated)
Study Completion	2036-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-21